Avacopan beneficial in ANCA-related vasculitis patients on rituximab
02 Dec 2023
Avacopan, when added to background induction therapy with rituximab, is as efficacious as a prednisone taper in terms of inducing remission at week 26 and is associated with a higher rate of sustained remission at week 52 in patients with antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, according to the phase III ADVOCATE trial.
Holistic skincare routine
linked to treatment outcomes
01 Dec 2023;
Professor Goh Chee-Leok, of the National Skin Centre, Singapore, discusses the importance of physician-led treatment and maintenance of skin conditions in patients with typical skin disease.
Sign Out
